USFDA approves EUA for bamlanivimab-etesevimab combo to treat Covid-19 patients

The U.S. Food and Drug Administration (FDA) has approved Emergency Use Authorization (EUA) for investigational bamlanivimab and etesevimab as a combination therapy for the treatment of mild to

The post USFDA approves EUA for bamlanivimab-etesevimab combo to treat Covid-19 patients appeared first on Pharmaceutical Business review.

This is not a CAPTIS article. Originally, it was published here.